Cizzle Biotechnology Holdings Plc, based in London, is a company that specializes in developing a blood test for the early detection of various forms of lung cancer. The company's focus is on developing the CIZ1B protein gene and its potential as a diagnostic biomarker for the detection and management of lung cancer. The Ciz1 protein promotes DNA replication, organization, and control, which could lead to better understanding and detection of lung cancer. The company was previously known as Cizzle Biotechnology Limited but changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Since its incorporation in 2004, the company has been dedicated to the development of early cancer detection solutions.